Marinus Pharmaceuticals Inc (MRNS)
1.31
-0.02
(-1.50%)
USD |
NASDAQ |
May 16, 12:26
Marinus Pharmaceuticals Cash from Financing (Quarterly): 0.257M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.257M |
| December 31, 2023 | 0.661M |
| September 30, 2023 | 25.90M |
| June 30, 2023 | 0.237M |
| March 31, 2023 | -0.174M |
| December 31, 2022 | 94.14M |
| September 30, 2022 | -0.546M |
| June 30, 2022 | 0.014M |
| March 31, 2022 | 31.13M |
| December 31, 2021 | 0.297M |
| September 30, 2021 | 28.08M |
| June 30, 2021 | 12.84M |
| March 31, 2021 | 0.096M |
| December 31, 2020 | 65.09M |
| September 30, 2020 | -0.106M |
| June 30, 2020 | 44.12M |
| March 31, 2020 | 0.117M |
| December 31, 2019 | 68.07M |
| September 30, 2019 | -0.018M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | -0.083M |
| December 31, 2018 | 42.30M |
| September 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2018 | 0.014M |
| March 31, 2018 | -0.193M |
| December 31, 2017 | 0.243M |
| September 30, 2017 | 45.82M |
| June 30, 2017 | -0.104M |
| March 31, 2017 | 1.635M |
| December 31, 2016 | -0.917M |
| September 30, 2016 | -1.001M |
| June 30, 2016 | -0.152M |
| March 31, 2016 | -0.101M |
| December 31, 2015 | 28.24M |
| September 30, 2015 | -0.032M |
| June 30, 2015 | 0.034M |
| March 31, 2015 | 0.20M |
| December 31, 2014 | 4.616M |
| September 30, 2014 | 41.80M |
| June 30, 2014 | 1.975M |
| March 31, 2014 | -0.082M |
| December 31, 2013 | 0.5017M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 7.554M |
| March 31, 2013 | -0.0079M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.546M
Minimum
Sep 2022
94.14M
Maximum
Dec 2022
18.51M
Average
0.277M
Median
Cash from Financing (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 12.18M |
| Soligenix Inc | -0.009M |
| Actinium Pharmaceuticals Inc | 14.77M |
| Macrogenics Inc | 0.248M |
| ADMA Biologics Inc | -1.447M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.46M |
| Cash from Investing (Quarterly) | 20.88M |
| Free Cash Flow | -113.98M |
| Free Cash Flow Per Share (Quarterly) | -0.6589 |
| Free Cash Flow to Equity (Quarterly) | -37.96M |
| Free Cash Flow Yield | -158.2% |